A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary disease (COPD). ⚠️study will only be conducted in research centers in Brazil (please do not send e-mail if your center is outside brazil).
Epistemonikos ID: 0731a0f5759a6680867024a8c6e15c7acc9e7976
First added on: May 07, 2024